EGFR-Mutated Advanced NSCLC: Enhancing Treatment Strategies and Patient Care With Novel Therapies : Episode 2
EGFR-Targeted Therapies in NSCLC: IV vs Subcutaneous Administration
Panelists discuss how amivantamab’s dual targeting of EGFR and MET may address resistance mechanisms and unmet needs in EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Dr Scott highlighting its potential clinical benefits, while Squires shares insights on managing the adverse event profile and strategies for managing adverse effects in patients receiving intravenous (IV) amivantamab.
Video content above is prompted by the following:
- Dr Scott addresses: How does amivantamab’s dual targeting of EGFR and MET potentially address resistance mechanisms and unmet needs in EGFR-mutated NSCLC?
- In your clinical experience, what makes a patient an ideal candidate for amivantamab?
- Dr Scott asks Squires: Based on your experience with patients receiving IV amivantamab, can you describe the typical adverse event profile and your strategies for managing these adverse effects?
Recent Videos
Related Content
